Do people with primary progressive MS reach a point over time where they stop experiencing new symptoms? If so, in what age range does this typically happen?
How many people on Tysabri experience a waning effect as they approach their next dose? How much does this effect impact their symptoms and quality of life?
Are people with MS who received the Johnson & Johnson Covid 19 vaccine and got blood clots due to it more susceptible to getting blood clots in the future?
More data/experience on ‘wearing off phenomenon’ with Ocrevus treatment. Can next infusion be administered at 5 months instead of 6 months to avoid this wearing off phenomenon?
For the 5-25 percent of MS patients who do not experience fatigue as a major symptom, is there a protective factor to be learned? Could we understand why they do not report having the most common symptom?
Do some MS patients who are/have taken Ocrevus have advancing disability when compared to other medications. In particular gait and mobility issues.